BACKGROUND: Positive sentinel lymph node (SLN) findings in ductal carcinoma in situ (DCIS) range from 1 to 22 % but have unknown biologic significance. This study sought to identify predictors of positive SLNs and to assess their clinical significance for patients with an initial diagnosis of DCIS. METHODS: The study identified 1234 patients with an initial diagnosis of DCIS who underwent SLN dissection (SLND) at our institution from 1997 through 2011. Positive SLN findings were categorized as isolated tumor cells (ITCs) (≤0.2 mm), micrometastases (>0.2-2 mm), or macrometastases (>2 mm). Predictors of positive SLNs were analyzed, and survival outcomes were examined. RESULTS: Positive SLN findings were identified in 132 patients (10.7 %): 66 patients with ITCs (5.4 %), 36 patients with micrometastases (2.9 %), and 30 patients with macrometastases (2.4 %). Upstaging to microinvasive (n = 68, 5.5 %) or invasive (n = 259, 21.0 %) cancer occurred for 327 patients (26.5 %). Factors predicting positive SLNs included diagnosis by excisional biopsy (odds ratio [OR] 1.90; P = 0.007), papillary histology (OR 1.77; P = 0.006), DCIS larger than 2 cm (OR 1.55; P = 0.030), more than three interventions before SLND (4 interventions: OR 2.04; P = 0.022; ≥5 interventions: OR 3.87; P < 0.001), and occult invasion (microinvasive: OR 3.44; P = 0.001; invasive: OR 6.21; P < 0.001). The median follow-up period was 61.7 months. Patients who had pure DCIS with and without positive SLNs had equivalent survival rates (100.0 vs 99.7 %; P = 0.679). Patients with occult invasion and positive SLNs had the worst survival rate (91.7 %; P < 0.001). CONCLUSIONS: Occult invasion and more than three total interventions were the strongest predictors of positive SLN findings in patients with an initial diagnosis of DCIS. This supports the theory of benign mechanical transport of breast epithelial cells. Except for patients at high risk for invasive disease, routine use of SLND in DCIS is not warranted.
BACKGROUND: Positive sentinel lymph node (SLN) findings in ductal carcinoma in situ (DCIS) range from 1 to 22 % but have unknown biologic significance. This study sought to identify predictors of positive SLNs and to assess their clinical significance for patients with an initial diagnosis of DCIS. METHODS: The study identified 1234 patients with an initial diagnosis of DCIS who underwent SLN dissection (SLND) at our institution from 1997 through 2011. Positive SLN findings were categorized as isolated tumor cells (ITCs) (≤0.2 mm), micrometastases (>0.2-2 mm), or macrometastases (>2 mm). Predictors of positive SLNs were analyzed, and survival outcomes were examined. RESULTS: Positive SLN findings were identified in 132 patients (10.7 %): 66 patients with ITCs (5.4 %), 36 patients with micrometastases (2.9 %), and 30 patients with macrometastases (2.4 %). Upstaging to microinvasive (n = 68, 5.5 %) or invasive (n = 259, 21.0 %) cancer occurred for 327 patients (26.5 %). Factors predicting positive SLNs included diagnosis by excisional biopsy (odds ratio [OR] 1.90; P = 0.007), papillary histology (OR 1.77; P = 0.006), DCIS larger than 2 cm (OR 1.55; P = 0.030), more than three interventions before SLND (4 interventions: OR 2.04; P = 0.022; ≥5 interventions: OR 3.87; P < 0.001), and occult invasion (microinvasive: OR 3.44; P = 0.001; invasive: OR 6.21; P < 0.001). The median follow-up period was 61.7 months. Patients who had pure DCIS with and without positive SLNs had equivalent survival rates (100.0 vs 99.7 %; P = 0.679). Patients with occult invasion and positive SLNs had the worst survival rate (91.7 %; P < 0.001). CONCLUSIONS: Occult invasion and more than three total interventions were the strongest predictors of positive SLN findings in patients with an initial diagnosis of DCIS. This supports the theory of benign mechanical transport of breast epithelial cells. Except for patients at high risk for invasive disease, routine use of SLND in DCIS is not warranted.
Authors: N Klauber-DeMore; L K Tan; L Liberman; S Kaptain; J Fey; P Borgen; A Heerdt; L Montgomery; M Paglia; J A Petrek; H S Cody; K J Van Zee Journal: Ann Surg Oncol Date: 2000-10 Impact factor: 5.344
Authors: Nils M Diaz; Charles E Cox; Mark Ebert; John D Clark; Vesna Vrcel; Nicholas Stowell; Anu Sharma; James W Jakub; Alan Cantor; Barbara A Centeno; Elisabeth Dupont; Carlos Muro-Cacho; Santo Nicosia Journal: Am J Surg Pathol Date: 2004-12 Impact factor: 6.394
Authors: Carolien H M van Deurzen; Peter Bult; Maaike de Boer; Ron Koelemij; Richard van Hillegersberg; Vivianne C G Tjan-Heijnen; Monique G G Hobbelink; Peter C de Bruin; Paul J van Diest Journal: Am J Surg Pathol Date: 2009-01 Impact factor: 6.394
Authors: Frans D Rahusen; Sybren Meijer; Annette H M Taets van Amerongen; Rik Pijpers; Paul J van Diest Journal: Breast J Date: 2003 Sep-Oct Impact factor: 2.431
Authors: Danielle Riley; Elizabeth A Chrischilles; Ingrid M Lizarraga; Mary Charlton; Brian J Smith; Charles F Lynch Journal: Breast Cancer Res Treat Date: 2022-01-24 Impact factor: 4.872
Authors: L M van Roozendaal; B Goorts; M Klinkert; K B M I Keymeulen; B De Vries; L J A Strobbe; C A P Wauters; Y E van Riet; E Degreef; E J T Rutgers; J Wesseling; M L Smidt Journal: Breast Cancer Res Treat Date: 2016-04-15 Impact factor: 4.872
Authors: Brigid K Killelea; Jessica B Long; Weixiong Dang; Sarah S Mougalian; Suzanne B Evans; Cary P Gross; Shi-Yi Wang Journal: Ann Surg Oncol Date: 2018-03-07 Impact factor: 5.344
Authors: Henry M Kuerer; Benjamin D Smith; Mariana Chavez-MacGregor; Constance Albarracin; Carlos H Barcenas; Lumarie Santiago; Mary E Edgerton; Gaiane M Rauch; Sharon H Giordano; Aysegul Sahin; Savitri Krishnamurthy; Wendy Woodward; Debasish Tripathy; Wei T Yang; Kelly K Hunt Journal: J Cancer Date: 2017-08-22 Impact factor: 4.207
Authors: William H Ward; Lyudmila DeMora; Elizabeth Handorf; Elin R Sigurdson; Eric A Ross; John M Daly; Allison A Aggon; Richard J Bleicher Journal: Ann Surg Oncol Date: 2019-09-27 Impact factor: 5.344
Authors: Peiyin Hung; Shi-Yi Wang; Brigid K Killelea; Sarah S Mougalian; Suzanne B Evans; Tannaz Sedghi; Cary P Gross Journal: JNCI Cancer Spectr Date: 2019-08-07